Profil
Drew Endy is the founder of Codon Devices, Inc. (founded in 2004) and Gen9, Inc. (founded in 2009).
At Codon Devices, he held the title of Director from 2004 to 2010.
At Gen9, he currently holds the title of Director.
Dr. Endy's current jobs include Chairman at The Biobricks Foundation and Professor-Stanford Bioengineering at Stanford University.
He previously worked as a Member at Massachusetts Institute of Technology.
Dr. Endy's education includes an undergraduate degree from Dartmouth College and an undergraduate degree from Lehigh University.
Postes actifs de Drew Endy
| Sociétés | Poste | Début |
|---|---|---|
The Biobricks Foundation
 The Biobricks Foundation Miscellaneous Commercial ServicesCommercial Services The Biobricks Foundation is a biotechnology organization that focuses on engineering biology to benefit all people and the planet. The non-profit company is based in Cambridge, MA. The company offers programs such as Bionet, OpenMTA, Free Genes, Biobrick Public Agreement, and SBX.0 Conferences. The foundation aims to make genes free and enable others to share their materials. | Président | - |
| Stanford University | Corporate Officer/Principal | - |
Gen9, Inc.
 Gen9, Inc. BiotechnologyHealth Technology Gen9, Inc. engages in the development of synthetic biology technologies. It transforms synthetic biology by creating technologies to increase innovation within several industries including biopharmaceuticals, fine chemicals and bio-fuels. The company was founded by Joseph M. Jacobson, George Church and Drew Endy in 2009 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2009 |
Anciens postes connus de Drew Endy
| Sociétés | Poste | Fin |
|---|---|---|
Codon Devices, Inc.
 Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Fondateur | 05/01/2010 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Formation de Drew Endy
| Dartmouth College | Undergraduate Degree |
| Lehigh University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Codon Devices, Inc.
Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Gen9, Inc.
Gen9, Inc. BiotechnologyHealth Technology Gen9, Inc. engages in the development of synthetic biology technologies. It transforms synthetic biology by creating technologies to increase innovation within several industries including biopharmaceuticals, fine chemicals and bio-fuels. The company was founded by Joseph M. Jacobson, George Church and Drew Endy in 2009 and is headquartered in Cambridge, MA. | Health Technology |
The Biobricks Foundation
The Biobricks Foundation Miscellaneous Commercial ServicesCommercial Services The Biobricks Foundation is a biotechnology organization that focuses on engineering biology to benefit all people and the planet. The non-profit company is based in Cambridge, MA. The company offers programs such as Bionet, OpenMTA, Free Genes, Biobrick Public Agreement, and SBX.0 Conferences. The foundation aims to make genes free and enable others to share their materials. | Commercial Services |